Travoprost 0.004%/timolol 0.5% fixed combination

Drugs of Today

Volumn 43, Issue 2, 2007, Pages 77-83

  Noecker, Robert J ^a   Awadallah, Nida S ^b   Kahook, Malik Y ^a  

^a University of Pittsburgh School of Medicine   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIMOLOL; TRAVOPROST;

BLEPHARITIS; BLURRED VISION; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORNEA DISEASE; CORNEAL STAINING; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE DISCOMFORT; EYE EDEMA; EYE PAIN; FOREIGN BODY REACTION; HUMAN; HYPEREMIA; HYPOTENSION; INTRAOCULAR HYPERTENSION; LUNG FUNCTION; MONOTHERAPY; NONHUMAN; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PHOTOPHOBIA; PRURITUS; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CLOPROSTENOL; DRUG COMBINATIONS; GLAUCOMA, OPEN-ANGLE; HUMANS; OCULAR HYPERTENSION; TIMOLOL;

EID: 34147220117     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.2.1032058     Document Type: Review

References (28)

1. Goldberg, I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthal 2003, 48 (Suppl. 1): S3-7.
2. Kass, M.A., Heuer, D.K., Higginbotham, E.J. et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary-open angle glaucoma. Arch Ophthalmol 2002, 120: 701-13.
3. Lichter, P.R., Musch, D.C., Gillespie, B.W. et al.; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001, 108: 1943-53.
4. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998, 126: 487-97.
5. Robin, A.L., Covert, D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005, 112: 863-8.
6. Hoy, S.M., Keam, S.J., Keating, G.M. Travoprost/timolol. Drugs Aging 2006, 23: 587-97.
7. European Agency for the Evaluation of Medicinal Products. The morning or evening at the same time each day in DuoTrav: European Public Assessment Report (EPAR). Available at: http://www.emea.eu.int/
8. Bron, A.J., Chidlow, G., Melena, J., Osborne, N.N. Beta-blocker in the treatment of glaucoma. In: Orgul, S., Flammer, J. (Eds.). Pharmacotherapy in glaucoma. Verlag Hans Huber, Seattle 2000, 79-113.
9. Ota, T., Aihara, M., Narumiya, S., Araie, M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 2005, 46: 4159-63.
10. Toris, C.B., Zhan, G.L., Camras, C.B., McLaughlin, M.A. Effects of travoprost on aqueous humor dynamics in monkeys. J Glaucoma 2005, 14: 70-3.
11. Barnebey, H., Orengo-Nania, S., Flowers, B.E. et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005, 140: 1-7.
12. Schuman, J.S., Katz, G.J., Lewis, R.A. et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005, 140: 242-50.
13. Hughes, B.A., Bacharach, J., Craven, E.R. et al. A three-month, multicenter, double-masked, study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open-angle glaucoma or ocular hypertension. J Glaucoma 2005, 14: 392-9.
14. Henry, J.C., Kessler, T.L., Mallick, S. et al. Travoprost/timolol Study Group comparison of the safety and IOP-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed combination to the concomitant administration of Xalatan® and timolol 0.5%. ARVO, Fort Lauderdale 2006, Abst. 446.
15. Topouzis, F., Melamed, S., Danesh-Meyer, H. et al. A one-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007, in press.
16. Denis, P., Andrew, R., Wells, D., Friren, B. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur J Ophthalmol 2006, 16: 407-15.
17. Parrish, R.K., Palmberg, P., Sheu, W.P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003, 135: 688-703.
18. Netland, P.A., Landry, T., Sullivan, E.K. et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001, 132: 472-84.
19. DuBiner. H.B., Sircy, M.D., Landry, T. et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004, 26: 35-47.
20. Zimmerman, T.J., Kass, M.A., Yablonski, M.E., Becker, B. Timolol maleate: Efficacy and safety. Arch Ophthalmol 1979, 97: 656-8.
21. Boger, W.P. 3rd, Steinert, R.F., Thomas, J.V. Timolol in the therapy of "ocular hypertension". Surv Ophthalmol 1980, 25: 195-202.
22. Patel, S.C., Spaeth, G,L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995, 26: 233-6.
23. Weinreb, R.N. Compliance with medical treatment of glaucoma. J. Glaucoma 1992, 1: 134-6.
24. Chrai, S.S., Makoid, M.C., Eriksen, S.P., Robinson, J.R. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974, 63: 333-8.
25. Ventura, M.P., Saheb, N.E., Solari, H.P., Saraiva, VS., Vianna, R.N., Burnier, M.N. Jr. Cost considerations of the new fixed combinations for glaucoma medical therapy. J Clin Pharm Ther 2005, 30: 251-4.
26. Noecker, R.J., Herrygers, L.A., Anwaruddin, R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004, 23: 490-6.
27. Gasset, A.R., Ishii, Y., Kaufman, H.E. et al. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974, 78: 98-105.
28. Mietz, H., Niesen, U., Kriegelstein, G.K. The effects of preservatives and antiglaucomatous medication on histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994, 232: 561-5.